Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential

Jefferies reiterated its Buy rating and $30 price target on Sarepta Therapeutics, implying roughly 64% upside from the $18.26 share price, and expects potentially value-creating siRNA readouts in DM1 and FSHD in 2H 2026, with each program representing a more than $1B opportunity. Sarepta's Q2 2026 EPS of $0.64 and revenue of $401.3M exceeded consensus estimates of $0.22 and $383M, respectively, but sales declined sharply because of weaker ELEVIDYS demand. Investor views remain divided: Mizuho maintains a $31 Outperform target, while H.C. Wainwright retains a $5 Sell target following Novartis' unsuccessful Phase 3 HARBOR study.

Analysis

SRPT is trading as a challenged commercial gene-therapy franchise with pipeline optionality rather than as a platform company. That framing creates upside if quarterly ELEVIDYS demand stabilizes: a modest improvement in patient starts, payer approvals, or inventory normalization would have a disproportionate effect on the equity because the current valuation leaves little credit for later-stage assets. Conversely, a further decline in franchise revenue would undermine the proposed valuation floor and raise concerns about funding a multi-indication development program without dilution.

The key distinction for the 2H26 siRNA readouts is biomarker translation. Early molecular signals can support platform value and financing flexibility, but functional benefit will be the metric that determines whether the market assigns meaningful probability to billion-dollar indications; this is likely a 6-18 month rerating process rather than an immediate commercial inflection. Novartis' negative read-through should not be treated as directly dispositive unless target biology, delivery, patient population, and endpoint sensitivity are comparable, but it does raise the market's required efficacy threshold for neuromuscular programs.

Near-term, SRPT remains vulnerable to post-earnings estimate cuts if underlying demand and gross-to-net dynamics deteriorate. The contrarian setup is attractive only if commercial KPIs confirm that the revenue weakness is transient; otherwise, the apparent asset-value discount can persist as pipeline spending consumes cash. The main falsifiers are another sequential decline in ELEVIDYS sales or guidance, material safety/regulatory restrictions, and Phase I/II data showing biomarker movement without a credible dose-response or functional path.

Key Decisions for Investors

• Keep SRPT on a catalyst watch rather than add aggressively before the next commercial update; require evidence of sequential stabilization in ELEVIDYS demand and no reduction in full-year guidance before underwriting the DMD-franchise valuation floor.
• For a high-risk biotech sleeve, initiate only a 50-100 bp starter long in SRPT ahead of 2H26 data, with a 12-18 month horizon; add only after DM1 data demonstrate dose-responsive biomarker activity. Target upside is a rerating toward the $30 analyst-value zone, while a renewed commercial miss or safety restriction should trigger an exit rather than averaging down.
• Use a long SRPT / short XBI pair only after commercial stabilization is verified, to isolate idiosyncratic platform and franchise recovery from broad biotech-beta volatility. Reassess the hedge around data releases, where SRPT-specific binary risk will dominate sector correlation.
• Do not position in NVS solely on the failed program's perceived read-through. Monitor whether SRPT discloses sufficiently comparable endpoint and functional data; absent comparability, the event is sentiment pressure on the category rather than a reliable fundamental negative for SRPT.